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Abstract 
Multimaterial bioprinting technologies offer promising avenues to create mini-organ models with 
enhanced tissue heterogeneity and complexity. This article focuses on the application of three-
dimensional bioprinting to fabricate organ-on-chip systems for in vitro drug testing and 
screening. We illustrate the capabilities and limitations of a bioprinting approach compared to 
microfabrication in constructing an organ-chip device. Further, we propose strategies in 
multimaterial integration for printing microphysiological tissue models. With these analyses, key 
challenges and future directions are highlighted. 
Keywords: Biomedical; Tissue; Fluidics; Biological synthesis (assembly); biomimetic 
(assembly). 
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Introduction 
In the last decade, we have seen tremendous progress in three-dimensional (3D) culture 
technologies, and the development of culture systems exhibiting more complex cellular 
interfaces than a conventional flat petri dish.1,2 These culture systems have been used for 
landmark developments in mini-organ models, such as organoids with realistic microanatomy,3 
and organ-on-a-chip systems in simulating tissue/organ-level physiology.4 Combined with 
advances in stem cell technologies, these culture systems are envisaged to fulfill roles in bridging 
gaps between preclinical and clinical models in the drug development pipeline, and ultimately, 
reducing costly failures in clinical trials.5,6 
While it is important to harness in vitro biological models to address specific questions, 
simple two-dimensional cultures cannot capture many of the key microenvironmental factors 
(Table I) known to influence cell fates. Culturing cells in a complex configuration, however, is 
labor-intensive and costly. Recent advances in bioprinting and biofabrication technologies offer 
promising new strategies to create tissue scaffolds and tissue models.  
Bioprinting can support the ability to repeatedly build small-scale tissue systems, 
minimizing human intervention and improving standardization and accuracy.7,8 Second, due to 
its ability to automate and program the deposition of cells and materials in 3D,9,10 bioprinting 
also provides new possibilities to construct a cell niche with prescribed complexity and 
physiological resemblance. These two general attributes may address some of the critical steps 
toward the adaption of complex culture systems. These include, for example, the necessity for 
standardization, validation, and reproducibility, and meeting investigators’ desires to create 
complex co-culture systems with more than four cell types, in a predefined spatial configuration 
(please see reference 2 for survey results). The latter attribute may be regarded as the key 
advantage not easily facilitated by microfabrication and lithography-based approaches.  
In this article, direct comparisons between 3D bioprinted and microfabricated organ-on-
a-chip models are presented. Further, we propose how a fit-for-purpose bioprinting process can 
be designed to construct cell niches for in vitro tissue and organ models. 
Comparison between bioprinted and microfabricated models 
A number of organ- and disease-on-a-chip models have been developed as a result of advanced 
microfluidic technologies.1,11 Mini-organ models have been established for various organs 
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including the lung,4 heart,12 kidney13 and liver.14 Simultaneously, disease models such as local 
cancer invasion and cancer transendothelial migration  have also been demonstrated.15 Among 
these, there are simple systems comprising a simple cell type within a microfluidic channel,16 to 
complex designs containing multicellular components coupled with 3D gels and circulation.17 D. 
Huh et al.18 and E. K. Sackmann et al.19 have summarized the progress to date.  
In comparison to the microfabricated platforms, the capability of 3D bioprinting has yet 
to be extensively exploited, though select functional tissue and organ models on a chip were 
recently demonstrated.8 With the main purpose of recreating aspects of microenvironmental 
cues, it is important to identify how a bioprinting approach resembles or differs from a 
microfabrication approach. Table I lists the main operating mechanisms associated with the 
respective technique in achieving the desired microenvironmental cues. We further present a 
side-by-side comparison between similar organ-chips and screening models generated by the two 
techniques in Table II. We highlight the key results shown in the two tables here. 
Although both microfluidics and bioprinting allow spatial organization of cells and 
extracellular matrix gels, the mechanisms facilitating these differ greatly. In microfluidic chips, 
materials are organized by flow paths in the channels, and therefore, compartmentalization and 
special flow geometries need to be designed to allow localized cell/ material seeding.32, 33 On the 
other hand, 3D printing can provide a more direct deposition approach through control of the 
nozzle position.34 However, in order to create vessel and tubule-like features, both techniques 
require flow-directed cell-seeding within a channel geometry.35  
Nonetheless, the convenience of bioprinting to integrate multiple cells, hydrogels, and 
even sensors has enabled the creation of liver,23, 24 heart,31 and skin21, 22 models with better 
biological functions. Lind et al.31 in a recent heart model reported that soft strain gauge sensors 
could be directly printed by a multimaterial printer and embedded in a printed cardiac tissue, 
enabling long-term and facile digital readouts of contractile stresses in the engineered tissue. 
Such one-step integration of on-chip sensors in tissue constructs is difficult to achieve by a 
microfabrication-based approach. Agarwal et al.12 developed a heart-on-a-chip system and 
showed that multistep assembly procedures were required to form the muscular thin-film (MTF) 
within the chip, which is also restricted by having a simple layered configuration; the system has 
benefits of being an autoclaveable and reusable device. 
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As shown in Table II, current bioprinting approaches offer lower planar resolution than 
microfluidics. For example, the creation of channel features is important for many purposes, 
including improving long-term cell viability by providing nutrient/waste exchange, imposing 
flow-induced shear, and incorporating dynamic concentration gradients. Lithography-based 
templating offers established protocols that facilitate the creation of these microchannel 
features.19 In contrast, achieving channels in bioprinting involves the use of fugitive inks and 
intricate ink removal procedures, also accompanied by poorer feature resolution of ~100 µm at 
the present.29  
For screening applications, one important practical consideration is the amount of cells 
and extracellular matrix materials required for forming a tissue model, and also the quantity of 
compounds needed for a drug test. So far, processes inherent in low-resolution cell printing lead 
to larger tissue sizes compared to the microfabricated chip systems; thus, larger quantities of 
cells and testing compounds, which can often be expensive or sparse, are required. On the other 
hand, if materials restrictions are not imposed, bioprinting provides the unique capability to 
create thick tissues by incorporating 3D interconnected channels or vessels for nutrient/waste 
exchange.30, 36  
As shown in Table II, a recent 3D vasculature printed from fugitive inks by Kolesky et 
al.30 was able to support a large bioprinted multicellular tissue (>1 cm in thickness) under long-
term perfusion (>6 weeks). In comparison, in established microfluidic chips, although the 
channel resolution and the resultant vasculature are finer, cell layout is usually much thinner in 
the planar fashion (<1 cm in thickness).28 Therefore, bioprinted thick tissue has advantages in 
capturing a higher degree of tissue heterogeneity and complexity37 and possibly providing closer 
physiological relevance in simulating realistic drug transport from circulation to the targeted 
tissues. 
Finally, nonflow related mechanical deformation can be seen as one of the most 
demanding microenvironmental factors to be integrated within a microphysiology device. In 
soft-lithography based microfluidics, the majority of the published work has harnessed the 
deformability of poly(dimethylsiloxane) (PDMS) to form pillars, valves, and stretchable 
membranes.12 Huh et al.4 provide a well-known example in the membrane-based double-layer 
lung-on-a-chip system. To mimic the mechanical deformation of the lung alveoli during the 
breathing motion, a vacuum pump was connected to two empty side channels to generate a cyclic 
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stretching motion on the PDMS membrane sandwiched between two layers of microchannels. 
Such a deformation mechanism imposes stringent demands on the robustness of the materials 
and device packaging, not yet achievable in a bioprinted construct at the microarchitectural level. 
Hölzl et al.38 and Arslan-Yildiz et al.39 show in their studies how mechanical forces were exerted 
on the bulk of bioprinted tissues utilizing a separate mechanical rig, which, however, is only 
viable for larger tissue constructs at a reduced test throughput. Nonetheless, continued 
improvements in print technology and the potential combination of microfabrication and 
bioprinting approaches can help address some of these technical challenges. 
Material integration for printing microenvironmental cues 
The integration among printed cells, extracellular matrices, and a miniature bioreactor can 
potentially lead to more precise and flexible recreation of the microenvironmental cues in vitro. 
To facilitate such a “bioprinted organ-chip” device, materials with diverse properties, from 
natural to synthetic in origin, need to be combined together to perform different roles in the 
device. Figure 1 summarizes different materials that have been used in bioprinting (not specific 
to organ-chips). The proposed materials functionality can be largely defined as being 
biologically focused, or structurally focused. For example, biologically active hydrogels can 
provide a matrix for cell encapsulation, cell binding, and a reservoir for growth factor release. 
The mechanical weakness of the biologically active hydrogels can be potentially overcome by 
combining with other robust hydrogels, or by designing mechanical supports from thermoplastic 
or thermoset structures.40 Examples include the creation of core–shell hydrogel structures 
between alginate and cell-embedded collagen,41 and the incorporation of nano- and microfibers42 
within hydrogels. The design of multiwell compartments using PDMS can also be seen as a 
strategy to provide structural support to the printed bioinks.37  
The diverse materials properties inevitably require different processing techniques for 
these materials. This means that print techniques based on direct a material dispensing 
mechanism may find broader applications with their cross-technique compatibility. Based on this 
concept, a number of commercial bioprinters have already established multinozzle deposition 
platforms. Ozbolat et al.9 and Gudapati et al.10 provide overviews of the different direct 
deposition printing mechanisms and their material suitability. Regardless of the technique, 
specific attention needs to be paid to the mismatched processing parameters between different 
materials. For example, thermoplastics are normally printed under elevated temperatures in a 
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molten form.34 However, this processing condition may affect the hydrated biological system if 
the solidified thermoplastic structure cannot be cooled rapidly. Any solvents or excess cross-
linking reagents contained in the thermoset material can also disturb biological behaviors.8 
Further, it is well known that process-induced thermal, mechanical, or photo stresses can 
dramatically decrease cellular viability.43 The processing time (i.e., the duration for which cells 
are taken out of the incubator environment) needs to be minimized.  
Finally, it is worth noting that many of the bioprinted constructs demonstrated so far 
consist of simple components, aimed at musculoskeletal applications, that can create robust, 
macroscopic tissues for implantation.36 The bioprinting techniques established from these 
experiences may need to be adjusted for printing soft, complex tissues for organ-chip devices. 
Considerations should be given to the self-assembly capability of different cell types; the matrix 
synthesis and remodeling ability of cells; and also the phase segregation phenomena of different 
material mixtures. These factors should be accounted for in designing a chip device to 
accommodate the tissue dynamics over long-term culture. 
Conclusion  
Advances in bioprinting are accelerating progress toward organ-on-a-chip devices for modeling 
tissue behaviors with enhanced physiological relevance. Integrating multiple printing techniques 
and material/cell libraries will provide new opportunities for making complex tissue models 
supporting long-term cultures; but one should be cautious in designing the fabrication strategy to 
accommodate the processing tolerances for different materials/cells.  
Continued developments in this area could bring higher print resolutions, incorporate 
dynamic mechanical stimulation, and integrate optical and electronic materials for in situ sensing 
and activation. Harnessing these functionalities will lead to smart organ-chip devices for high-
content pharmaceutical screening with low-reagent usage. The examples illustrated in this article 
stem from an engineering technology development prospective.  
The successful creation and implementation of an in vitro model relies heavily on in-
depth understanding of the biological pathways and physiological systems; and this will require 
significant collaborative efforts with biomedical researchers to fine-tune and optimize the culture 
conditions. As an intermediate step, 3D bioprinting can be seen as an invaluable toolkit to 
facilitate easy customization of the culture conditions, enabling systematic evaluation of the 
different microenvironmental cues (and their combinations) to realize a particular biological 
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phenotype. Like all in vitro model systems, for bioprinted organ-chips to have a real impact on 
drug development, one should design the level of biological model complexity, corresponding to 
the stage of the preclinical testing required. Ongoing system validation, in vivo–in vitro 
correlation, and regulatory approvals should be sought. 
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Figure and Figure Captions 
 
Table I. Reproducing microenvironmental cues using established lithography-based 
microfluidics and three-dimensional (3D) bioprinting. Engineering strategies, capabilities, and 
limitations of both techniques are compared. 
 
Note: ECM, extracellular matrix; PDMS, poly(dimethylsiloxane); 2D, two-dimensional. 
 
 
 
 
 
 
 
Table II. Side-by-side comparison of microengineered tissue/organ models via established 
microfabrication versus three-dimensional (3D) bioprinting techniques. 
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Note: hMSC, human mesenchymal stem cell; hiPS-CM, human-induced pluripotent stem cell-
derived cardiomyocytes; PU, polyurethane; ECM, extracellular matrix; HiPSC, human-induced 
pluripotent stem cell; μBBB, microfluidic blood–brain barrier; DBB, droplet-based bioprinting; 
EBB, extrusion-based bioprinting; DLP, digital light processing; LIFT, laser-induced forward 
transfer; GelMA, gelatin methacryloyl; GMHA, glycidyl methacrylate-hyaluronic acid; RGD, 
arginine-glycine-aspartic acid; PDMS, poly(dimethylsiloxane). 
 
 
 
 
 
 
 
 
 
Figure 1. Word cloud diagrams illustrating the statistics of literature reports on materials 
selection, bioprinting parameters, and the bioprinted cells and tissues. The relative size of each 
word/phrase is an indication of the relative abundance of the reported subject from Scopus and 
Web of Science (February 2017), in comparison to the other subjects in the same category. The 
stiffness ranking of the cells as well as tissue and organs are based on their reported in vivo 
native ECM/tissue stiffness. Note: GelMA, gelatin methacryloyl; GMHA, glycidal methacrylate-
hyaluronic acid; PLA, polylactic acid; PCL, polycaprolactone; PEGDA, polyethylene glycol 
diacrylate; PU, polyurethane; PDMS, poly(dimethylsiloxane); ESC, embryonic stem cell; MSC, 
mesenchymal stem cell; PEG, polyethylene glycol. 
